Lord, Abbett & Co
NKTR icon

Lord, Abbett & Co’s Nektar Therapeutics NKTR Stock Holding History

Lord, Abbett & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6M Sell
381,624
-23,456
-6% -$1.72M 0.08% 269
2026
Q1 		$29.1M Buy
+405,080
New +$23.1M 0.1% 227

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lord, Abbett & Co's NKTR Position: Q2 2026 in Review

Lord, Abbett & Co reduced its Nektar Therapeutics (NKTR) stake by 5.8% in Q2 2026, selling an estimated $1.72M and leaving 381,624 shares worth $26.6M. The position accounts for 0.08% of the portfolio, ranked #269.

Lord, Abbett & Co first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. The position peaked at $29.1M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Lord, Abbett & Co held 381,624 shares of Nektar Therapeutics worth $26.6M as of Q2 2026.
  • Lord, Abbett & Co sold 23,456 Nektar Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Nektar Therapeutics made up 0.08% of Lord, Abbett & Co's portfolio in Q2 2026, its #269 holding.
  • Lord, Abbett & Co first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Lord, Abbett & Co's Nektar Therapeutics position peaked at $29.1M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.